TR201909743T4 - Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. - Google Patents
Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. Download PDFInfo
- Publication number
- TR201909743T4 TR201909743T4 TR2019/09743T TR201909743T TR201909743T4 TR 201909743 T4 TR201909743 T4 TR 201909743T4 TR 2019/09743 T TR2019/09743 T TR 2019/09743T TR 201909743 T TR201909743 T TR 201909743T TR 201909743 T4 TR201909743 T4 TR 201909743T4
- Authority
- TR
- Turkey
- Prior art keywords
- compositions containing
- oral dosage
- delayed release
- release oral
- containing amorphous
- Prior art date
Links
- 230000003111 delayed effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 2
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical group C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 abstract 1
- 238000007496 glass forming Methods 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Abstract
Mevcut buluş, (A) amorf bardoksolon metil ve cam yapıcı bir eksipiyenden oluşan parçacıkları, (B) hidroksipropil metil selülozdan oluşan parçacıklarla karıştırılmış halde içeren bir katı dozaj formunu temin etmektedir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15260809P | 2009-02-13 | 2009-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201909743T4 true TR201909743T4 (tr) | 2019-07-22 |
Family
ID=42335073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/09743T TR201909743T4 (tr) | 2009-02-13 | 2010-02-12 | Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. |
Country Status (29)
Country | Link |
---|---|
US (2) | US8747901B2 (tr) |
EP (2) | EP2395979B1 (tr) |
JP (1) | JP5775464B2 (tr) |
KR (2) | KR101483203B1 (tr) |
CN (2) | CN102387789A (tr) |
AU (1) | AU2010213594B2 (tr) |
BR (1) | BRPI1008023B8 (tr) |
CA (1) | CA2752048C (tr) |
CO (1) | CO6361904A2 (tr) |
CY (2) | CY1119595T1 (tr) |
DK (2) | DK2395979T3 (tr) |
EA (1) | EA023652B1 (tr) |
ES (2) | ES2731601T3 (tr) |
HK (1) | HK1220130A1 (tr) |
HR (2) | HRP20171639T1 (tr) |
HU (2) | HUE044005T2 (tr) |
IL (1) | IL214258A (tr) |
LT (2) | LT3254675T (tr) |
MX (1) | MX2011008344A (tr) |
MY (1) | MY173715A (tr) |
NO (1) | NO2395979T3 (tr) |
NZ (1) | NZ594488A (tr) |
PL (2) | PL2395979T3 (tr) |
PT (2) | PT2395979T (tr) |
SG (1) | SG173601A1 (tr) |
SI (2) | SI2395979T1 (tr) |
TR (1) | TR201909743T4 (tr) |
WO (1) | WO2010093944A2 (tr) |
ZA (1) | ZA201105630B (tr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
AU2009203941B2 (en) | 2008-01-11 | 2015-03-12 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids and methods of use in the treatment of disease |
BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
SI2276493T1 (sl) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals, Inc. | Antioksidantni modulatorji vnetja: derivati oleanolne kisline z amino in drugimi modifikacijami pri C-17 |
TWI442925B (zh) | 2008-04-18 | 2014-07-01 | Reata Pharmaceuticals Inc | 抗氧化性發炎調節劑:c-環飽和之齊墩果酸衍生物 |
WO2010011782A1 (en) | 2008-07-22 | 2010-01-28 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
AU2010213594B2 (en) | 2009-02-13 | 2013-11-14 | Reata Pharmaceuticals Holdings, LLC | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
SI2558105T1 (sl) | 2010-04-12 | 2020-02-28 | Reata Pharmaceuticals, Inc. | Bardoksolon metil za zdravljenje debelosti |
ME02973B (me) | 2010-12-17 | 2018-07-20 | Reata Pharmaceuticals Inc | Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije |
EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
HUE053113T2 (hu) | 2012-04-27 | 2021-06-28 | Reata Pharmaceuticals Inc | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
ES2731758T3 (es) | 2012-09-10 | 2019-11-18 | Reata Pharmaceuticals Inc | Derivados de alcanodiil y alquenodiil de c17 del ácido oleanólico y métodos de uso de los mismos |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
BR112016003454B1 (pt) | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | Uso de composto de metil bardoxolona |
US20170333450A1 (en) | 2014-10-31 | 2017-11-23 | The Regents Of The University Of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
WO2016130927A1 (en) | 2015-02-12 | 2016-08-18 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
CN108290922B (zh) | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
WO2018089539A1 (en) | 2016-11-08 | 2018-05-17 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
PE20191490A1 (es) | 2016-12-16 | 2019-10-21 | Reata Pharmaceuticals Inc | DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS |
WO2019014412A1 (en) | 2017-07-13 | 2019-01-17 | Pliva Hrvatska D.O.O. | NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE |
US11708463B2 (en) | 2018-04-06 | 2023-07-25 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
TW202038918A (zh) | 2018-11-27 | 2020-11-01 | 日商協和麒麟股份有限公司 | 醫藥組合物 |
KR20230022164A (ko) | 2020-05-09 | 2023-02-14 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법 |
WO2022126129A1 (en) | 2020-12-11 | 2022-06-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids for use in therapy |
CN114558019A (zh) * | 2022-03-26 | 2022-05-31 | 中国科学院昆明动物研究所 | 一种Rab13基因抑制剂及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
JP4315182B2 (ja) * | 2006-10-30 | 2009-08-19 | ミツミ電機株式会社 | カメラモジュール |
JP2008247898A (ja) | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
AU2009203941B2 (en) | 2008-01-11 | 2015-03-12 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids and methods of use in the treatment of disease |
AU2010213594B2 (en) * | 2009-02-13 | 2013-11-14 | Reata Pharmaceuticals Holdings, LLC | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
-
2010
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active IP Right Grant
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en active Application Filing
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Application Discontinuation
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
-
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
-
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
-
2017
- 2017-10-26 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
-
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201909743T4 (tr) | Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. | |
EA201170616A1 (ru) | Лекарственная форма ацетаминофен/трамадол с замедленным действием для перорального приема | |
MX336741B (es) | Composiciones farmaceuticas de moduladores de c-met. | |
MY160456A (en) | Benzodiazepine bromodomain inhibitor | |
EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
IL204521A0 (en) | Oxadiazole derivatives, their preparation and pharmaceutical compositions containing them | |
MX2012007507A (es) | Compuestos de heteroarilo y usos de los mismos. | |
SG171542A1 (en) | Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin | |
EP2447253A4 (en) | DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
WO2012009723A8 (en) | C-met modulator pharmaceutical compositions | |
EP2624815B8 (en) | Oral vaccine fast-dissolving dosage form using starch | |
EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
WO2011104652A3 (en) | Veterinary compositions | |
EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
WO2014076712A3 (en) | Lurasidone hydrochloride solid dispersion | |
PL2504331T3 (pl) | Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
TR200908237A2 (tr) | Kalsiyum ve D vitamini içeren farmasötik bileşimler. | |
WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання | |
AU2009235968A8 (en) | Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | |
TR201000689A1 (tr) | Sefprozil içeren katı dozaj formlar. | |
TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
WO2009013594A3 (en) | Process for the preparation of controlled-release solid formulations containing oxcarbazepine, and formulations obtainable by said process |